Transforming Anxiety & Mood Disorder Therapeutics: Advancing Lymphatic-targeting Prodrugs for Next-Generation Neuropsychiatric Medicine
- Advancing clinically validated mechanisms with established efficacy and safety which have historically been limited by high first-pass metabolism, low bioavailability, and/or side effects, by applying the Glyph™ platform, a lymphatic-targeting prodrug technology, to overcome those limitations and invent innovative oral therapies
- Aiming to expand the clinical use of allopregnanolone, an endogenous neurosteroid with established antidepressant, anxiolytic, and sleep-promoting effects, through GlyphAllo (SPT-300), a novel, oral prodrug of allopregnanolone, designed to enhance oral bioavailability and enable once-daily oral dosing for patients with major depressive disorder
- Working toward enabling access to a clinically validated anxiolytic and antidepressant with GlyphAgo (SPT-320), a novel, oral prodrug of agomelatine, designed to enhance bioavailability and reduce pharmacokinetic variability compared to unmodified agomelatine at doses projected to reduce or eliminate the current need for routine liver function testing